Stat3 Signaling Pathway: A Future Therapeutic Target for Bone-Related Diseases

被引:46
作者
Li, Jiadong
Yin, Zhifeng
Huang, Biaotong
Xu, Ke
Su, Jiacan
机构
[1] Institute of Translational Medicine, Shanghai University, Shanghai
[2] School of Medicine, Shanghai University, Shanghai
[3] School of Life Sciences, Shanghai University, Shanghai
[4] Department of Orthopedics, Shanghai Zhongye Hospital, Shanghai
基金
国家重点研发计划; 中国国家自然科学基金;
关键词
stat3; bone-related diseases; target therapeutic; signaling pathway; biological functions; PHOSPHORYLATION; OSTEOARTHRITIS; OSTEOCLASTOGENESIS; TRANSCRIPTION; INFLAMMATION; ACTIVATION; AXIS; IL-6; ERK;
D O I
10.3389/fphar.2022.897539
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Signal transducer and activator of transcription 3 (Stat3) is activated by phosphorylation and translocated to the nucleus to participate in the transcriptional regulation of DNA. Increasing evidences point that aberrant activation or deletion of the Stat3 plays a critical role in a broad range of pathological processes including immune escape, tumorigenesis, and inflammation. In the bone microenvironment, Stat3 acts as a common downstream response protein for multiple cytokines and is engaged in the modulation of cellular proliferation and intercellular interactions. Stat3 has direct impacts on disease progression by regulating mesenchymal stem cells differentiation, osteoclast activation, macrophage polarization, angiogenesis, and cartilage degradation. Here, we describe the theoretical basis and key roles of Stat3 in different bone-related diseases in combination with in vitro experiments and animal models. Then, we summarize and categorize the drugs that target Stat3, providing potential therapeutic strategies for their use in bone-related diseases. In conclusion, Stat3 could be a future target for bone-related diseases.
引用
收藏
页数:8
相关论文
共 67 条
[1]   Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution [J].
Bharadwaj, Uddalak ;
Kasembeli, Moses M. ;
Robinson, Prema ;
Tweardy, David J. .
PHARMACOLOGICAL REVIEWS, 2020, 72 (02) :486-526
[2]  
Cai C., 2021, FRONT PHARMACOL, V12, P772540, DOI [10.3389/fphar.2021.772540, DOI 10.3389/FPHAR.2021.772540]
[3]   Neobavaisoflavone inhibits osteoclastogenesis through blocking RANKL signalling-mediated TRAF6 and c-Src recruitment and NF-κB, MAPK and Akt pathways [J].
Chen, Huiwen ;
Fang, Chao ;
Zhi, Xin ;
Song, Shaojun ;
Gu, Yanqiu ;
Chen, Xiaofei ;
Cui, Jin ;
Hu, Yan ;
Weng, Weizong ;
Zhou, Qirong ;
Wang, Yajun ;
Wang, Yao ;
Jiang, Hao ;
Li, Xiaoqun ;
Cao, Liehu ;
Chen, Xiao ;
Su, Jiacan .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (16) :9067-9084
[4]   STAT3 activation by catalpol promotes osteogenesis-angiogenesis coupling, thus accelerating osteoporotic bone repair [J].
Chen, Liang ;
Zhang, Ri-Yan ;
Xie, Jun ;
Yang, Jia-Yi ;
Fang, Kang-Hao ;
Hong, Chen-Xuan ;
Yang, Rong-Bo ;
Bsoul, Najeeb ;
Yang, Lei .
STEM CELL RESEARCH & THERAPY, 2021, 12 (01)
[5]   Targeted inhibition of STAT3 as a potential treatment strategy for atherosclerosis [J].
Chen, Qi ;
Lv, Jianjun ;
Yang, Wenwen ;
Xu, Baoping ;
Wang, Zheng ;
Yu, Zihao ;
Wu, Jiawei ;
Yang, Yang ;
Han, Yuehu .
THERANOSTICS, 2019, 9 (22) :6424-6442
[6]   RANKL signaling in bone marrow mesenchymal stem cells negatively regulates osteoblastic bone formation [J].
Chen, Xiao ;
Zhi, Xin ;
Wang, Jun ;
Su, Jiacan .
BONE RESEARCH, 2018, 6
[7]   Genistein inhibits angiogenesis developed during rheumatoid arthritis through the IL-6/JAK2/STAT3/VEGF signalling pathway [J].
Cheng, Wen-Xiang ;
Huang, Huan ;
Chen, Jian-Hai ;
Zhang, Tian-Tian ;
Zhu, Guo-Yuan ;
Zheng, Zheng-Tan ;
Lin, Jie-Tao ;
Hu, Yi-Ping ;
Zhang, Yong ;
Bai, Xue-Ling ;
Wang, Yan ;
Xu, Zhan-Wang ;
Song, Bing ;
Mao, Yi-Ying ;
Yang, Fei ;
Zhang, Peng .
JOURNAL OF ORTHOPAEDIC TRANSLATION, 2020, 22 :92-100
[8]   EGFL7 Is Expressed in Bone Microenvironment and Promotes Angiogenesis via ERK, STAT3, and Integrin Signaling Cascades [J].
Chim, Shek Man ;
Kuek, Vincent ;
Chow, Siu To ;
Lim, Bay Sie ;
Tickner, Jennifer ;
Zhao, Jinmin ;
Chung, Rosa ;
Su, Yu-Wen ;
Zhang, Ge ;
Erber, Wendy ;
Xian, Cory J. ;
Rosen, Vicki ;
Xu, Jiake .
JOURNAL OF CELLULAR PHYSIOLOGY, 2015, 230 (01) :82-94
[9]   The JAK inhibitor Tofacitinib inhibits structural damage in osteoarthritis by modulating JAK1/TNF-alpha/IL-6 signaling through Mir-149-5p [J].
Chiu, Yen-Shuo ;
Bamodu, Oluwaseun Adebayo ;
Fong, Iat-Hang ;
Lee, Wei-Hwa ;
Lin, Chih-Cheng ;
Lu, Chen-Hsu ;
Yeh, Chi-Tai .
BONE, 2021, 151
[10]   Regulation of STAT3 and its role in cardioprotection by conditioning: focus on non-genomic roles targeting mitochondrial function [J].
Comita, Stefano ;
Femmino, Saveria ;
Thairi, Cecilia ;
Alloatti, Giuseppe ;
Boengler, Kerstin ;
Pagliaro, Pasquale ;
Penna, Claudia .
BASIC RESEARCH IN CARDIOLOGY, 2021, 116 (01)